Phreesia (NYSE:PHR) Rating Reiterated by DA Davidson

DA Davidson reaffirmed their neutral rating on shares of Phreesia (NYSE:PHR) in a report published on Friday, Benzinga reports. DA Davidson currently has a $32.00 price target on the stock.

Other equities analysts also recently issued research reports about the stock. KeyCorp cut their price objective on shares of Phreesia from $40.00 to $30.00 and set an overweight rating on the stock in a report on Thursday, December 7th. Needham & Company LLC reiterated a buy rating and issued a $29.00 price target on shares of Phreesia in a report on Friday. JMP Securities restated a market outperform rating and issued a $28.00 price objective on shares of Phreesia in a research report on Friday. Raymond James restated an outperform rating and issued a $30.00 price objective (up previously from $25.00) on shares of Phreesia in a research report on Friday. Finally, Barclays assumed coverage on Phreesia in a research report on Wednesday, January 3rd. They set an overweight rating and a $29.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Phreesia currently has an average rating of Moderate Buy and an average target price of $32.71.

Phreesia Trading Down 3.5 %

Shares of NYSE:PHR traded down $0.82 on Friday, hitting $22.93. 693,167 shares of the company’s stock were exchanged, compared to its average volume of 545,245. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.02 and a quick ratio of 2.02. The business’s 50 day simple moving average is $25.31 and its two-hundred day simple moving average is $20.99. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -9.10 and a beta of 0.93. Phreesia has a 12 month low of $12.05 and a 12 month high of $36.13.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.02. The firm had revenue of $95.00 million during the quarter, compared to the consensus estimate of $93.52 million. Phreesia had a negative return on equity of 52.97% and a negative net margin of 38.42%. The firm’s quarterly revenue was up 24.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.72) earnings per share. Analysts anticipate that Phreesia will post -1.47 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Allison C. Hoffman sold 1,316 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $24.55, for a total transaction of $32,307.80. Following the completion of the sale, the general counsel now directly owns 144,464 shares of the company’s stock, valued at approximately $3,546,591.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Evan Roberts sold 2,247 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $24.55, for a total transaction of $55,163.85. Following the completion of the sale, the chief operating officer now directly owns 795,613 shares of the company’s stock, valued at approximately $19,532,299.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Allison C. Hoffman sold 1,316 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $24.55, for a total value of $32,307.80. Following the sale, the general counsel now directly owns 144,464 shares of the company’s stock, valued at $3,546,591.20. The disclosure for this sale can be found here. Insiders sold 9,950 shares of company stock valued at $246,213 in the last three months. 5.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the company. International Assets Investment Management LLC boosted its stake in shares of Phreesia by 1,987.3% in the 4th quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock valued at $34,000 after buying an additional 1,411 shares during the period. Captrust Financial Advisors lifted its stake in Phreesia by 154.6% during the second quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock worth $36,000 after purchasing an additional 866 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Phreesia during the first quarter worth approximately $43,000. State of Wyoming increased its position in Phreesia by 34.6% during the second quarter. State of Wyoming now owns 1,918 shares of the company’s stock worth $59,000 after buying an additional 493 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Phreesia by 85.4% during the third quarter. Tower Research Capital LLC TRC now owns 3,137 shares of the company’s stock worth $80,000 after buying an additional 1,445 shares during the period. 94.37% of the stock is currently owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.